2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial

Autor:	A. Gomez, E. Aranda, Encarnación González-Flores, Pilar García-Alfonso, M.J. Safont, Jose Ignacio Martin-Valades, M. Mendez-Urena, Manuel Benavides, C. Lopez, E. Falcó, Carmen Guillén-Ponce, Eduardo Díaz-Rubio, Cristina Grávalos, Beatriz García-Paredes, Jose Luis Manzano, M. Navalon, Julia Alcaide, A. Sanchez-Ruiz, Rafael López, T. García-García
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty Cetuximab Colorectal cancer business.industry First line Treatment outcome Phases of clinical research medicine.disease Maintenance therapy Internal medicine RAS Mutation medicine In patient business medicine.drug
Zdroj:	European Journal of Cancer. 51:S371-S372
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(16)31044-9
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e9e388ed36c6cb0bb606936cbba3653a https://doi.org/10.1016/s0959-8049(16)31044-9 Zobrazit plný text záznamu Full Text from ScienceDirect